NYU Langone Medical Center

环球视野，深度视角 各位亲爱的股东，大家早上好中午好晚上好。 呃，看不懂标题很正常。 我们先看事，再来一点点捋一捋这个标题里面的一些细节。 #01 “这次不一样” 2024年12月18日，一位女性表示猪肾挽救了的生命。 接受异种器官移植并不是新鲜事，这位名叫Towana Looney的现年53岁美国女性在2024年11月25日完成了肾脏移植手术，并在11天后出院。 本次手术，由纽约大学朗格尼医学中心的Robert Montgomery博士领导，这也是基因编辑猪肾脏异种移植手术。 只不过，之前的患者要么个把月就去世了，或者病危了。 呃，话说Towana Looney也就才做完一个月的手术啊…… 不管怎么说，我们是希望她能够康复。 Looney曾在1999年为母亲捐献过一个肾脏，但后来的妊娠并发症导致高血压，损害了她仅存的肾脏，最终完全失去功能。 她是一个英雄。 那么，我们的疑问并没有消除。 为啥移植猪的器官大多数无法正常存活？她用的这个肾脏是来自哪家公司的手笔？ #02 困难重重 20世纪70年代以来，器官移植已经成为肾功能衰竭和其他器官疾病患者的切实选择。然而，器官短缺的问题一直存在。 在美国，大概有10.4万人等待器官移植，这里面就有9.04万人需要肾脏移植。 而相对的，只有2.7万人在2023年完成了肾脏移植手术。 这就有着巨大的需求-供给断层，异种器官移植无疑是一种可能行得通的解决方案，毕竟什么3D打印器官还远远没到可用的程度。 华中科技大学同济医院器官移植研究陈忠华教授是这么解释为啥要用猪而不是猴子啥的。 “我们在历史上选择过非人类的灵长类动物（NHP），如猴子、黑猩猩和狒狒，早期是做过很多的研究，但是没有一个真正意义上的长期成功。第一，人类控制不了排斥反应；第二，灵长类的动物不可能工业化、大规模地去饲养；第三，非人类的灵长类动物跟人的基因非常相似，所以它携带的疾病、传染病也更容易传给人类。例如，猩猩容易得的某些疾病，也可以通过器官移植传染给人，再在人类进行流行。所以不得不放弃灵长类。   找来找去猪是比较适合的。第一，人类从开始吃猪肉起，就慢慢适应了猪的蛋白质；第二，因为猪和人类的基因关系比较远，它的传染病很少会传染给人类；第三，猪可以大规模工业化生产；最后，也是最重要的，我们现在的畜牧业对于猪的基因改良技术已经很成熟，它可以改良成更适合被人类接受的器官。比如说我们现在看到的四基因、五基因、十基因编辑等等，都是针对性改良以后的品种。” 但是，要完成异种器官移植确是困难重重。 首先是排异问题。 当我们的免疫系统将新器官视为外来器官时，会发生排斥反应。 解决方法是通过基因编辑技术，把产生排异反应的相关基因编辑掉，让人的免疫系统不再攻击。 第二，跨物种传染病问题。 解决方法是通过无菌环境饲养，产生DPF（Designated Pathogen Free，即无指定致病菌猪）猪，且运输、使用过程严格无菌管理。 即便如此，还有一个比较头疼的问题。 第三，猪内源性逆转录病毒（PERV） 猪内源性逆转录病毒（porcine endogenous retrovirus，PERV）整合在基因组中，是一种跨物种传播的逆转录病毒。 本来通过DPF能够避免绝大多数病原体的风险，然而PERV这货是整合在猪的基因组的，隐藏的杀手啊…… 目前解决方案是……还是用基因编辑。 我把这整合进基因组的PERV序列干掉不就得了？然而这货有62个copy。 目前看到的报道是杭州启函已经解决了这个问题，CEO 杨璐菡博士的导师是George Church。 对，那个男人…… 那么，这次患者用的肾又是来自哪里呢？ #03 为治愈而生 该名患者使用的猪肾脏来自美国Revivicor公司，他们甚至给这项“产品”注册了商标，叫UKidney。 该款“产品”采用了10基因编辑技术，删除CGTA1/CMAH等4个基因，增加DAF/CD46等6个基因。 呃，没看到PERV的处理。 不过，Revivicor最后还有个质控阶段，相信应该会筛选没有PERV的供体吧…… Revivicor也是目前我们已知商业化进展最快的异种器官移植解决方案公司，公司拥有2个DPF工厂，能够达到年产250例基因工程器官。 Revivicor是传奇公司United Therapeutics的子公司，这是一家为治愈而诞生的公司。 1996年，United Therapeutics成立。 这家公司的首要使命就是拯救创始人的女儿，她罹患有肺动脉高压（pulmonary arterial hypertension，PAH）。 顺便，公司在1997年上了个市…… 2002年，公司第一个皮下注射治疗PAH的产品Remodulin获得FDA批准，随后2004年获准静脉输注给药。 2013年，该公司治疗PAH的口服药物Orenitram获批上市，公司股价也随之开启飙升模式。 截至2024年12月19日，公司股价已高达360美元。 自上市以来，公司累计涨幅高达5235%。 2024Q3公司营收高达7.49亿美元，拥有现金或现金等价物46亿美元。 而United Therapeutics的传奇大部分都要归功于他们的传奇CEO Martin （Martine ） Rothblatt。 #04 “炸裂本炸” Martin （Martine） Rothblatt，拥有MBA、哲学博士、法学博士学位，当然这也只是传奇的冰山一角。 Martin Rothblatt 1954年出生于一个犹太家庭，母亲是语言矫正师，父亲是牙医。 大学进入大名鼎鼎的UCLA（加州大学洛杉矶分校），两年后休学环游世界，对的，有钱人的标配。 1974年，在环游世界的时候对卫星通讯技术产生兴趣，随后返回学校学习通讯技术并在1977年以优异的成绩毕业。 凭借关于卫星广播技术的论文，Martin得以加入UCLA的法学博士和MBA的联合培养计划，并于1981年顺利拿到双学位。 短暂律所经历后Martin在1986年成为Geostar的CEO，然而这不是重点。 1990年他离开Geostar创办了两家公司WorldSpace 和Sirius。 其中后者于1994年上市，目前市值约69.81亿美元，最高市值曾经高达数百亿美元。 然而，这还不是重点。 1994年，Martin变成了Martine。 我懂，朋友，你跟我一样有许多问号。 但是，这并不足以完全展示他/她炸裂的人生。 这离不开他/她的妻子Bina Aspen的支持，两人1982年结婚。 结婚前，两人各有一个孩子，并相互收养了对方的孩子。 呃，别问，我也不懂why...wiki上这么写的。 请想象下，结婚后又生了2个孩子的枕边人突然在12年后告诉你，其实我是个女人。 这在炸裂界也是相当炸裂的，不过Bina选择支持他/她。 于是，经过雌激素和手术“治疗”后，Martin Rothblatt变成了Martine Aliana Rothblatt。 不过，想想对方是个亿万富豪，大多数人还是会选择原谅，哦不，是支持吧？ 如果你觉得这已经足够炸裂了，其实还有更炸裂的。 2010年，Martine做了一款机器人，名叫BINA48。 哦，他/她老婆Bina并没有受到伤害，Martine只是想有朝一日能够将意识上传到机器而已。 血肉苦弱，机械飞升。 没错，他/她就是炸裂本炸。 #05 不止于此 回到正事。 United Therapeutics的器官相关产品线远远不止异种肾一款，实际上在公司管线里面就有8款在研产品。 其中既有异种器官移植产品，也有基于3D打印生物制造的产品和人工肝脏/肾脏产品。 UKidney如果能够成功，United Therapeutics也许会有更大的想象空间。 所以，你觉得160亿美元的市值贵吗？ END 啊对对对对，扫描这货 能联系到我 至此，各位股东星标了么？点赞了么？转发了么？在看了么？谢谢！ 所有内容均不作为投资建议，信息均来自公开资料。 近期文章： 一项MRD临床试验宣布失败 AZ：他还是那么喜欢数字PCR 融了8000万美元的Pleno在造什么“飞机”？ 转折点！中国空间蛋白组学工具开始涌现 David Liu的Chroma&Nvelop决定合并 Editas：天塌了 相关资料：注1：https://abcnews.go.com/GMA/Wellness/woman-speaks-after-receiving-gene-edited-pig-kidney/注2：https://www.sohu.com/a/254398818_810120注3：https://achievement.org/achiever/martine-rothblatt-ph-d/注4：https://ir.unither.com/~/media/Files/U/United-Therapeutics-IR/documents/events-and-presentations/2024-10-30-3q-eps-presentation.pdf

New project cycle aims to improve diabetes outcomes among low-income immigrant populations NEW YORK, Nov. 25, 2024 /PRNewswire/ -- The Centers for Disease Control and Prevention (CDC) has renewed funding for the NYU-CUNY Prevention Research Center (NYU-CUNY PRC) on a new project cycle focused on chronic disease prevention and management in underserved communities, using innovative community-clinical linkage strategies. Continue Reading Health worker tests patient's blood sugar The NYU-CUNY PRC, one of 20 CDC-designated centers in the national network of PRCs, was established in 2009 to advance translation of evidence-based and innovative programs to increase access to care and disrupt the cycle of health disparities among hard-to-reach, marginalized populations. Its research studies are based in NYU Langone's Department of Population Health and at the CUNY Graduate School of Public Health and Health Policy (CUNY SPH). The core research project for the 2024-2029 cycle aims to improve diabetes management among low-income immigrant populations through culturally tailored education and support. The project will test a multi-level Community-Clinical Linkage (CCL) model that integrates a technology-enabled platform for accessing social care, Community Health Workers (CHWs) as case managers, and mobile health-based diabetes education and support to help patients bring their blood sugar under control. "By bridging the gap between clinical services and community-based support, we can reach people who experience significant barriers in their day-to-day lives that prevent them from effectively managing their diabetes," says CUNY SPH Distinguished Professor Terry Huang, NYU-CUNY PRC co-director and a principal investigator on the core research study. Other principal investigators on the core research study include NYU Langone faculty Drs. Brita Roy and Lu Hu. Using culturally adapted strategies for diabetes management and prevention, the investigators hope to see improved health outcomes for this population, enhanced capacity for community partners to adopt and implement evidence-based interventions effectively and the development of a portfolio of tools and resources that can be disseminated widely across healthcare systems serving diverse populations. The NYU-CUNY PRC will leverage existing partnerships with healthcare providers, municipal agencies, and community organizations to enhance the delivery and sustainability of interventions. It will include training workshops and technical assistance for external partners engaged in CCL initiatives. "As the only CDC-funded prevention research center based in New York City, our vision is to serve as the premier citywide and national resource to support community-clinical linkage models," says Dr. Nadia Islam, professor and director of Translational Research Partners at NYU Grossman School of Medicine's Department of Population Health and MPI of the NYU-CUNY PRC. "Working closely with community-based, municipal, and healthcare partners, our center has played a leading role advancing the science of effective, replicable, and scalable CHW models and programs to improve health equity across diverse populations." "We're very proud this innovative public-private partnership continues to thrive, where between a CEPH-accredited, minority-serving public school of public health (CUNY SPH) and a leading academic medical school with expertise in population health and prevention research (NYU) work together to promote health equity and social justice in NYC," says Dr. Lorna Thorpe, the Anita Steckler and Joseph Steckler professor and chair of the Department of Population Health at NYU Langone. Along with the parent NYU-CUNY PRC, the CDC also funded four special interest projects within the NYU-CUNY PRC network: Advancing Research in Immunization Services Network (ARISe) led by CUNY SPH Distinguished Lecturer Scott Ratzan and NYU Langone Assistant Professor Lauren Taylor. The NYU-CUNY PRC is funded to serve as both a coordinating center and collaborating center. Cancer Prevention and Control Research Network (CPCRN) led by NYU Langone Professor Chau Trinh-Shevrin, with Distinguished Professor Huang as a co-investigator. The NYU-CUNY PRC is funded as collaborating center. Managing Epilepsy Well Network (MEW) led by NYU Langone Associate Professor Tanya Spruill. The NYU-CUNY PRC is funded as a collaborating center. Gauging men's reaction to relabeling of GG1 prostate cancer and understanding of pathology reports led by NYU Langone Professor Stacy Loeb, in partnership with colleagues at the University of California, San Francisco. For media inquiries, contact: Ariana Costakes [email protected] About CUNY SPH The CUNY Graduate School of Public Health and Health Policy (CUNY SPH) is committed to promoting and sustaining healthier populations in New York City and around the world through excellence in education, research, and service in public health and by advocating for sound policy and practice to advance social justice and improve health outcomes for all. About NYU Langone NYU Langone Health is a world-class, patient-centered, integrated academic medical center, with a culture rooted in excellence in patient care, education, and research. Vizient, Inc., has ranked NYU Langone the #1 comprehensive academic medical center in the country for three years in a row and U.S. News & World Report recently placed nine of its clinical specialties among the top five in the nation. NYU Langone offers a comprehensive range of medical services across six inpatient locations, its Perlmutter Cancer Center, and more than 300 outpatient locations across the New York area and Florida. The system also includes two medical schools, in Manhattan and on Long Island, and a vast research enterprise. SOURCE CUNY SPH WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

NEW YORK, Nov. 21, 2024 /PRNewswire/ -- A surgical team at NYU Langone Health has performed the first fully robotic double lung transplant in the world. The procedure marks a breakthrough in the potential of robotic surgery and minimally invasive patient care, making NYU Langone the new leader in robotic transplant surgery around the globe. Stephanie H. Chang, MD, surgical director of the Lung Transplant Program at the NYU Langone Transplant Institute, and patient Cheryl Mehrkar discuss the world's first fully robotic double& lung transplant performed at& NYU Langone Health on Oct. 22, 2024 in New York, NY. Video by NYU Langone Health. Animation illustrating the steps involved in the world's first fully robotic double lung transplant surgery that took place at NYU Langone Health on Oct. 22, 2024 in New York, NY. Animation by Rubber Ring Creative for NYU Langone Health. Shahin Mehrkar (left) and his wife Cheryl Mehrkar, who received the world’s first fully robotic double lung transplant surgery on Oct. 22, 2024, at NYU Langone Health, with Stephanie H. Chang, MD, associate professor in the Department of Cardiothoracic Surgery at NYU Grossman School of Medicine and surgical director of the Lung Transplant Program for the NYU Langone Transplant Institute. Photo by NYU Langone Health